SANUWAVE Q3 revenue $9.4M (+89% YoY), operating income $2.0M; Q4 guidance 40-50% growth

SANUWAVE Health, Inc.

2024-Q3 EPS reported -$5.92 revenue$22,308,000

Revenue record of $9.4M, up 89% vs Q3 2023; beat guidance of 65-75% increase.
UltraMist systems sold: 124 in Q3 2024 vs 55 in Q3 2023; consumables revenue $5.4M (+75%).
GAAP operating income $2.0M vs loss of $0.5M in Q3 2023; Adj. EBITDA $2.1M vs ($0.3M).
Net loss $20.7M (driven by derivative liability fair value change); year-to-date loss $18.6M.
Guides Q4 2024 revenue $9.7-10.5M (+40-50% YoY); FY2024 revenue >$32M; 1-for-375 reverse split Oct 18.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.